Wells Fargo analyst Tiago Fauth raised the firm’s price target on Tectonic Therapeutic (TECX) to $79 from $55 and keeps an Overweight rating on the shares. No SAEs/discontinuations/ISRs/ADAs materially mitigate safety risk, while the exposure-response model is unique for the class and de-risking of the PD, significantly mitigating the risk of leaving efficacy on the table, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX:
- Tectonic Therapeutic Inc. Reports Q3 2024 Results
- Tectonic Therapeutic price target raised to $69 from $49 at Leerink
- Tectonic Therapeutic reports Q3 EPS ($1.20), consensus (82c)
- Navigating Uncertainty: Tectonic Therapeutic’s Clinical Data Volatility and Its Impact on Business Stability
- Tectonic Therapeutic director buys $1.44M in common stock